Lutris Pharma
Anticancer Therapy for Patients Treated with EGFR Inhibitors
Company Overview
Snapshot
Founded in December 2015, Lutris Pharma operates with 1–10 employees. The company has raised over $40.69 million across four funding rounds from six investors. In January 2025, Lutris Pharma secured funding with Columbus Venture Partners and Pontifax.
Business overview
Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting side effects. The company develops proprietary small molecules, such as the topical B-Raf inhibitor LUT014, to allow patients to continue epidermal growth factor receptor (EGFR) inhibitor treatments without interruptions caused by typical skin toxicities. Leveraging the paradoxical effect of B-Raf inhibitors, LUT014 aims to decrease dermal toxicities and reduce acneiform lesions associated with EGFR inhibitors. Lutris Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical industry.
Strategic signal
Lutris Pharma completed enrollment in its Phase 2 trial of LUT014 in October 2024, evaluating its efficacy for treating EGFR inhibitor-induced acneiform rash in metastatic colorectal cancer patients. This milestone indicates significant progress in the clinical development of their lead product, signaling to investors a clear advancement towards potential market entry and addressing a critical unmet need in oncology patient care.
Log in to access full profile ›Company Intelligence Q&A
- What is Lutris Pharma's primary focus?
- Lutris Pharma is focused on developing therapies to improve anticancer treatment effectiveness and patient quality of life by reducing cutaneous side effects associated with EGFR inhibitors.
- What is LUT014?
- LUT014 is a proprietary topical B-Raf inhibitor developed by Lutris Pharma. It is designed to mitigate dermal toxicities and acneiform lesions caused by EGFR inhibitors, thereby allowing patients to continue their anticancer therapy.
- When did Lutris Pharma complete enrollment for its Phase 2 trial of LUT014?
- Lutris Pharma completed enrollment in its Phase 2 trial of LUT014 for the treatment of EGFR inhibitor-induced acneiform rash in patients with metastatic colorectal cancer in October 2024.
- Has Lutris Pharma received any grants for its research?
- In October 2022, Lutris Pharma's founder received a grant from the California Institute of Regenerative Medicine (CIRM) to develop LUT017 for wound healing.
- What was a recent funding event for Lutris Pharma?
- In January 2025, Lutris Pharma raised funding, with Columbus Venture Partners and Pontifax participating.